0001179110-14-002710.txt : 20140213
0001179110-14-002710.hdr.sgml : 20140213
20140213160744
ACCESSION NUMBER: 0001179110-14-002710
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20131202
FILED AS OF DATE: 20140213
DATE AS OF CHANGE: 20140213
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MERRIMACK PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001274792
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: SUITE B7201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-441-1000
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: SUITE B7201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mulroy Robert J.
CENTRAL INDEX KEY: 0001531563
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35409
FILM NUMBER: 14606118
MAIL ADDRESS:
STREET 1: MERRIMACK PHARMACEUTICALS, INC.
STREET 2: ONE KENDALL SQUARE, SUITE B7201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2013-12-02
0
0001274792
MERRIMACK PHARMACEUTICALS INC
MACK
0001531563
Mulroy Robert J.
C/O MERRIMACK PHARMACEUTICALS, INC.
ONE KENDALL SQUARE, SUITE B7201
CAMBRIDGE
MA
02139
1
1
0
0
President and CEO
Common Stock
2013-12-02
5
W
0
E
58290
0
D
931354
I
By Trust
Common Stock
2013-12-02
5
W
0
E
9715
0
A
941069
D
Stock Option (right to buy)
5.02
2014-02-11
4
A
0
300000
0
A
2024-02-10
Common Stock
300000
300000
D
The reporting person was previously a trustee of a trust created as a result of a bequest. All shares of the issuer held by such trust were previously reported as beneficially owned by the reporting person on a Form 4 filed on 2/13/13. The reported transactions represent the dissolution of such trust and the distribution of a portion of the shares held by such trust to the reporting person. The shares that were distributed to other beneficiaries are not reportable by the reporting person.
This option vests as to 1/12th of the total number of shares on 5/11/14 and an additional 1/12th of the total number of shares at the end of each successive three month period thereafter until 2/11/17.
/s/ Jeffrey A. Munsie, attorney-in-fact
2014-02-13